NCT05018013

Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression

Efficacy and Safety of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression: A Multicenter, Randomized, Double-blind, Double-dummy, Active- and Placebo-controlled, Parallel-group, Phase II Study

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 240 (estimated)
• Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of Ammoxetine hydrochloride enteric-coated tablets in subjects with depression.

Detailed description

In this study, a randomized, double-blind, duloxetine hydrochloride enteric coated capsule positive and placebo-controlled multicenter study was used to evaluate the efficacy and safety of different doses of amxetine hydrochloride enteric coated tablets in the treatment of depression.

Conditions

• Major Depressive Disorder (MDD)

Interventions

Type	Name	Description
DRUG	Ammoxetine hydrochloride enteric-coated tablets	Ammoxetine hydrochloride enteric-coated tablets
DRUG	Duloxetine hydrochloride enteric-coated capsules	Duloxetine hydrochloride enteric-coated capsules
DRUG	Placebo to Ammoxetine	Placebo to Ammoxetine
DRUG	Placebo to Duloxetine	Placebo to Duloxetine

Timeline

• Start date: 2021-08-21
• Primary completion: 2022-08-01
• Completion: 2022-12-30
• First posted: 2021-08-24
• Last updated: 2021-11-12

Locations

1 site across 1 country: China